Michael Cruse - 02 Mar 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Role
Chief Operating Officer
Signature
/s/ Vineet R. Jindal, Attorney-in-Fact
Issuer symbol
OKUR
Transactions as of
02 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Mar 2022, 20:51:44 UTC
Previous filing
14 Dec 2021
Next filing
31 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPHM Stock option (right to buy) Award $0 +25,000 $0.000000 25,000 02 Mar 2022 Common Stock 25,000 $4.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in a series of 48 successive equal monthly installments measured from March 2, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.